

Lisa Stamp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7246976/publications.pdf>

Version: 2024-02-01

181
papers

6,597
citations

76326

40
h-index

82547

72
g-index

184
all docs

184
docs citations

184
times ranked

6749
citing authors

#	ARTICLE	IF	CITATIONS
1	Gout. Lancet, The, 2016, 388, 2039-2052.	13.7	774
2	Mapping and predicting mortality from systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1897-1905.	0.9	410
3	Gout. Nature Reviews Disease Primers, 2019, 5, 69.	30.5	326
4	Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol. Arthritis and Rheumatism, 2012, 64, 2529-2536.	6.7	230
5	Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study. Annals of the Rheumatic Diseases, 2015, 74, 908-911.	0.9	184
6	Myeloperoxidase and oxidative stress in rheumatoid arthritis. Rheumatology, 2012, 51, 1796-1803.	1.9	180
7	Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. Journal of Rheumatology, 2006, 33, 1646-50.	2.0	160
8	Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nature Reviews Rheumatology, 2016, 12, 235-242.	8.0	139
9	Diet and Rheumatoid Arthritis: A Review of the Literature. Seminars in Arthritis and Rheumatism, 2005, 35, 77-94.	3.4	121
10	Hyperuricaemia and gout: time for a new staging system?. Annals of the Rheumatic Diseases, 2014, 73, 1598-1600.	0.9	118
11	GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes. Annals of the Rheumatic Diseases, 2017, 76, 869-877.	0.9	114
12	A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Annals of the Rheumatic Diseases, 2017, 76, 1522-1528.	0.9	107
13	A strong role for the ABCG2 gene in susceptibility to gout in New Zealand Pacific Island and Caucasian, but not Māori, case and control sample sets. Human Molecular Genetics, 2010, 19, 4813-4819.	2.9	100
14	New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert. Arthritis and Rheumatology, 2018, 70, 1702-1709.	5.6	86
15	Sugar-sweetened beverage consumption: a risk factor for prevalent gout with <i>SLC2A9</i> genotype-specific effects on serum urate and risk of gout. Annals of the Rheumatic Diseases, 2014, 73, 2101-2106.	0.9	77
16	Native Joint Septic Arthritis: Epidemiology, Clinical Features, and Microbiological Causes in a New Zealand Population. Journal of Rheumatology, 2015, 42, 2392-2397.	2.0	75
17	Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Nature Reviews Rheumatology, 2017, 13, 561-568.	8.0	74
18	Gout and its comorbidities: implications for therapy. Rheumatology, 2013, 52, 34-44.	1.9	72

#	ARTICLE	IF	CITATIONS
19	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1592-1600.	0.9	72
20	The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion. <i>Nature Communications</i> , 2020, 11, 2767.	12.8	71
21	Clinically Insignificant Effect of Supplemental Vitamin C on Serum Urate in Patients With Gout: A Pilot Randomized Controlled Trial. <i>Arthritis and Rheumatism</i> , 2013, 65, 1636-1642.	6.7	68
22	Brief Report: Validation of a Definition of Flare in Patients With Established Gout. <i>Arthritis and Rheumatology</i> , 2018, 70, 462-467.	5.6	68
23	Clinical Utility of Multi- γ Energy Spectral Photon Counting Computed Tomography in Crystal Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1158-1162.	5.6	65
24	Gout in Solid Organ Transplantation. <i>Drugs</i> , 2005, 65, 2593-2611.	10.9	64
25	Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual- γ Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial. <i>Arthritis and Rheumatology</i> , 2019, 71, 1739-1746.	5.6	64
26	Modulation of Genetic Associations with Serum Urate Levels by Body-Mass-Index in Humans. <i>PLoS ONE</i> , 2015, 10, e0119752.	2.5	64
27	Discordant association of the CREBRF rs373863828 A allele with increased BMI and protection from type 2 diabetes in Māori and Pacific (Polynesian) people living in Aotearoa/New Zealand. <i>Diabetologia</i> , 2018, 61, 1603-1613.	6.3	61
28	Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 367-376.	1.5	57
29	Effects of Changing from Oral to Subcutaneous Methotrexate on Red Blood Cell Methotrexate Polyglutamate Concentrations and Disease Activity in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 2540-2547.	2.0	54
30	Multiplicative interaction of functional inflammasome genetic variants in determining the risk of gout. <i>Arthritis Research and Therapy</i> , 2015, 17, 288.	3.5	54
31	Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2065-2070.	0.9	53
32	Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action. <i>Arthritis Research and Therapy</i> , 2012, 14, R138.	3.5	49
33	Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. <i>Arthritis Care and Research</i> , 2016, 68, 667-672.	3.4	48
34	Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 457-464.	3.4	48
35	The use of "low dose methotrexate in rheumatoid arthritis" are we entering a "new era of therapeutic drug monitoring and pharmacogenomics?". <i>Biomedicine and Pharmacotherapy</i> , 2006, 60, 678-687.	5.6	46
36	Predicting allopurinol response in patients with gout. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 277-289.	2.4	46

#	ARTICLE	IF	CITATIONS
37	Population-specific Resequencing Associates the ATP-binding Cassette Subfamily C Member 4 Gene With Gout in New Zealand Māori and Pacific Men. <i>Arthritis and Rheumatology</i> , 2017, 69, 1461-1469.	5.6	46
38	Serum Urate as a Soluble Biomarker in Chronic Gout—Evidence that Serum Urate Fulfills the OMERACT Validation Criteria for Soluble Biomarkers. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 40, 483-500.	3.4	45
39	The genetics of gout: towards personalised medicine?. <i>BMC Medicine</i> , 2017, 15, 108.	5.5	44
40	Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 536-544.	0.9	44
41	Impaired response or insufficient dosage?—Examining the potential causes of “inadequate response” to allopurinol in the treatment of gout. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 170-174.	3.4	43
42	How to prevent allopurinol hypersensitivity reactions?. <i>Rheumatology</i> , 2018, 57, i35-i41.	1.9	43
43	Monocyte Derived Interleukin (IL)-23 Is an Important Determinant of Synovial IL-17A Expression in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2009, 36, 2403-2408.	2.0	41
44	Furosemide increases plasma oxypurinol without lowering serum urate—a complex drug interaction: implications for clinical practice. <i>Rheumatology</i> , 2012, 51, 1670-1676.	1.9	38
45	Gout, Rheumatoid Arthritis, and the Risk of Death Related to Coronavirus Disease 2019: An Analysis of the UK Biobank. <i>ACR Open Rheumatology</i> , 2021, 3, 333-340.	2.1	37
46	Performance of classification criteria for gout in early and established disease. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 178-182.	0.9	36
47	Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities. <i>Nature Reviews Rheumatology</i> , 2021, 17, 633-641.	8.0	36
48	Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia. <i>Rheumatology</i> , 2014, 53, 1958-1965.	1.9	35
49	Survey Definitions of Gout for Epidemiologic Studies: Comparison With Crystal Identification as the Gold Standard. <i>Arthritis Care and Research</i> , 2016, 68, 1894-1898.	3.4	34
50	Association between ABCG2 rs2231142 and poor response to allopurinol: replication and meta-analysis. <i>Rheumatology</i> , 2018, 57, 656-660.	1.9	34
51	Urate crystal deposition and bone erosion in gout: “inside-out” or “outside-in”? A dual-energy computed tomography study. <i>Arthritis Research and Therapy</i> , 2016, 18, 208.	3.5	33
52	Safety profile of anti-gout agents. <i>Current Opinion in Rheumatology</i> , 2014, 26, 162-168.	4.3	32
53	Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 293-301.	3.4	32
54	Allopurinol and kidney function: An update. <i>Joint Bone Spine</i> , 2016, 83, 19-24.	1.6	31

#	ARTICLE	IF	CITATIONS
55	Hydrogen sulfide acts as a pro-inflammatory mediator in rheumatic disease. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 182-189.	1.9	31
56	The Toll-Like Receptor 4 (TLR4) Variant rs2149356 and Risk of Gout in European and Polynesian Sample Sets. <i>PLoS ONE</i> , 2016, 11, e0147939.	2.5	31
57	Hyperuricaemia: contributions of urate transporter ABCG2 and the fractional renal clearance of urate. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1363-1366.	0.9	30
58	Mitochondrial genetic variation and gout in Māori and Pacific people living in Aotearoa New Zealand. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 571-578.	0.9	30
59	Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locus. <i>Rheumatology</i> , 2020, 59, 2544-2549.	1.9	30
60	Interaction of the GCKR and A1CF loci with alcohol consumption to influence the risk of gout. <i>Arthritis Research and Therapy</i> , 2017, 19, 161.	3.5	29
61	Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout. <i>Arthritis Research and Therapy</i> , 2020, 22, 45.	3.5	28
62	Positive association of tomato consumption with serum urate: support for tomato consumption as an anecdotal trigger of gout flares. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 196.	1.9	27
63	An association of smoking with serum urate and gout: A health paradox. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 825-842.	3.4	27
64	Diagnostic Arthrocentesis for Suspicion of Gout Is Safe and Well Tolerated. <i>Journal of Rheumatology</i> , 2016, 43, 150-153.	2.0	25
65	Population-specific association between ABCG2 variants and tophaceous disease in people with gout. <i>Arthritis Research and Therapy</i> , 2017, 19, 43.	3.5	25
66	Body mass index modulates the relationship of sugar-sweetened beverage intake with serum urate concentrations and gout. <i>Arthritis Research and Therapy</i> , 2015, 17, 263.	3.5	24
67	Efficacy of a Rheumatoid Arthritis-Specific Smoking Cessation Program: A Randomized Controlled Pilot Trial. <i>Arthritis Care and Research</i> , 2017, 69, 28-37.	3.4	24
68	The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial. <i>Arthritis Research and Therapy</i> , 2017, 19, 283.	3.5	24
69	Bringing It All Together: A Novel Approach to the Development of Response Criteria for Chronic Gout Clinical Trials. <i>Journal of Rheumatology</i> , 2011, 38, 1467-1470.	2.0	23
70	The relationship between ferritin and urate levels and risk of gout. <i>Arthritis Research and Therapy</i> , 2018, 20, 179.	3.5	23
71	Associations of Gout and Baseline Serum Urate Level With Cardiovascular Outcomes: Analysis of the Coronary Disease Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 1733-1738.	5.6	23
72	Prevention and treatment of gout. <i>Nature Reviews Rheumatology</i> , 2019, 15, 68-70.	8.0	23

#	ARTICLE	IF	CITATIONS
73	Allopurinol hypersensitivity: Pathogenesis and prevention. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101501.	3.3	23
74	Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review. <i>Arthritis Research and Therapy</i> , 2021, 23, 130.	3.5	23
75	Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction. <i>Arthritis Care and Research</i> , 2022, 74, 1649-1658.	3.4	23
76	Molecular mechanism of an adverse drug-drug interaction of allopurinol and furosemide in gout treatment. <i>Biochemical and Biophysical Research Communications</i> , 2014, 452, 157-162.	2.1	22
77	Expert opinion on emerging urate-lowering therapies. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 201-209.	2.4	22
78	Urate-Lowering Therapy: Current Options and Future Prospects for Elderly Patients with Gout. <i>Drugs and Aging</i> , 2014, 31, 777-786.	2.7	20
79	Patient Information about Gout: An International Review of Existing Educational Resources. <i>Journal of Rheumatology</i> , 2015, 42, 975-978.	2.0	20
80	Multi-energy photon-counting computed tomography versus other clinical imaging techniques for the identification of articular calcium crystal deposition. <i>Rheumatology</i> , 2021, 60, 2483-2485.	1.9	20
81	Screening for hyperuricaemia and gout: a perspective and research agenda. <i>Nature Reviews Rheumatology</i> , 2014, 10, 752-756.	8.0	19
82	Development of a patient-reported outcome measure of tophus burden: the Tophus Impact Questionnaire (TIQ-20). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2144-2150.	0.9	19
83	Interactions between serum urate-associated genetic variants and sex on gout risk: analysis of the UK Biobank. <i>Arthritis Research and Therapy</i> , 2019, 21, 13.	3.5	19
84	The comparative effect of exposure to various risk factors on the risk of hyperuricaemia: diet has a weak causal effect. <i>Arthritis Research and Therapy</i> , 2021, 23, 75.	3.5	19
85	Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study. <i>Lancet Rheumatology, The</i> , 2022, 4, e274-e281.	3.9	19
86	Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials. <i>Lancet Rheumatology, The</i> , 2022, 4, e53-e60.	3.9	18
87	Serum Urate in Chronic Gout – Will It Be the First Validated Soluble Biomarker in Rheumatology?. <i>Journal of Rheumatology</i> , 2011, 38, 1462-1466.	2.0	17
88	Individualising the dose of allopurinol in patients with gout. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2015-2026.	2.4	17
89	Digital-PCR for gene expression: impact from inherent tissue RNA degradation. <i>Scientific Reports</i> , 2017, 7, 17235.	3.3	17
90	Multiplexed Nanopore Sequencing of HLA-B Locus in Māori and Pacific Island Samples. <i>Frontiers in Genetics</i> , 2018, 9, 152.	2.3	17

#	ARTICLE	IF	CITATIONS
91	Dual-Energy Computed Tomography for Detection and Characterization of Monosodium Urate, Calcium Pyrophosphate, and Hydroxyapatite. <i>Investigative Radiology</i> , 2021, 56, 417-424.	6.2	17
92	Allopurinol Initiation and All-Cause Mortality Among Patients With Gout and Concurrent Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2022, 175, 461-470.	3.9	17
93	Association of SLC2A9 genotype with phenotypic variability of serum urate in pre-menopausal women. <i>Frontiers in Genetics</i> , 2015, 6, 313.	2.3	16
94	Replication of association of the apolipoprotein A1-C3-A4 gene cluster with the risk of gout. <i>Rheumatology</i> , 2016, 55, 1421-1430.	1.9	16
95	Mediation analysis to understand genetic relationships between habitual coffee intake and gout. <i>Arthritis Research and Therapy</i> , 2018, 20, 135.	3.5	16
96	Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting Requirements. <i>Journal of Rheumatology</i> , 2018, 45, 419-424.	2.0	15
97	Winds of change in imaging of calcium crystal deposition diseases. <i>Joint Bone Spine</i> , 2019, 86, 665-668.	1.6	15
98	The MÅori and Pacific specific CREBRF variant and adult height. <i>International Journal of Obesity</i> , 2020, 44, 748-752.	3.4	15
99	Intensive Serum Urate Lowering With Oral Urateâ€Lowering Therapy for Erosive Gout: A Randomized Doubleâ€Blind Controlled Trial. <i>Arthritis and Rheumatology</i> , 2022, 74, 1059-1069.	5.6	15
100	Expression of Methotrexate Transporters and Metabolizing Enzymes in Rheumatoid Synovial Tissue. <i>Journal of Rheumatology</i> , 2013, 40, 1519-1522.	2.0	14
101	Association between environmental exposures and granulomatosis with polyangiitis in Canterbury, New Zealand. <i>Arthritis Research and Therapy</i> , 2015, 17, 333.	3.5	14
102	A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 71-78.	1.9	14
103	Lack of effect of tart cherry concentrate dose on serum urate in people with gout. <i>Rheumatology</i> , 2020, 59, 2374-2380.	1.9	14
104	Gout and Organ Transplantation. <i>Current Rheumatology Reports</i> , 2012, 14, 165-172.	4.7	13
105	Tapering Biologic Therapy for Rheumatoid Arthritis: A Qualitative Study of Patient Perspectives. <i>Patient</i> , 2020, 13, 225-234.	2.7	12
106	Treatment advances in gout. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101719.	3.3	12
107	Developing a Tailored Smoking Cessation Intervention for Rheumatoid Arthritis Patients. <i>Musculoskeletal Care</i> , 2016, 14, 2-14.	1.4	11
108	The impact of diuretic use and <i>ABCG2</i> genotype on the predictive performance of a published allopurinol dosing tool. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 937-943.	2.4	11

#	ARTICLE	IF	CITATIONS
109	Population-specific factors associated with fractional excretion of uric acid. <i>Arthritis Research and Therapy</i> , 2019, 21, 234.	3.5	11
110	Effect of body mass index on serum urate and renal uric acid handling responses to an oral inosine load: experimental intervention study in healthy volunteers. <i>Arthritis Research and Therapy</i> , 2020, 22, 259.	3.5	11
111	Flare Rate Thresholds for Patient Assessment of Disease Activity States in Gout. <i>Journal of Rheumatology</i> , 2021, 48, 293-298.	2.0	11
112	Towards development of core domain sets for short term and long term studies of calcium pyrophosphate crystal deposition (CPPD) disease: A framework paper by the OMERACT CPPD working group. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 946-950.	3.4	11
113	Sugar Sweetened Beverage Consumption among Adults with Gout or Type 2 Diabetes. <i>PLoS ONE</i> , 2015, 10, e0125543.	2.5	10
114	Lack of direct evidence for natural selection at the candidate thrifty gene locus, PPARCC1A. <i>BMC Medical Genetics</i> , 2016, 17, 80.	2.1	10
115	Association analysis of the beta-3 adrenergic receptor Trp64Arg (rs4994) polymorphism with urate and gout. <i>Rheumatology International</i> , 2016, 36, 255-261.	3.0	10
116	Management of Gout in a Hospital Setting: A Lost Opportunity. <i>Journal of Rheumatology</i> , 2017, 44, 1493-1498.	2.0	10
117	Conjugation of urate-derived electrophiles to proteins during normal metabolism and inflammation. <i>Journal of Biological Chemistry</i> , 2018, 293, 19886-19898.	3.4	10
118	Do Serum Urate-Associated Genetic Variants Differentially Contribute to Gout Risk According to Body Mass Index? Analysis of the UK Biobank. <i>Arthritis and Rheumatology</i> , 2020, 72, 1184-1191.	5.6	10
119	Reassessing the Cardiovascular Safety of Febuxostat: Implications of the Febuxostat versus Allopurinol Streamlined Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 721-724.	5.6	10
120	Why compare the effectiveness of suboptimal gout management?. <i>Nature Reviews Rheumatology</i> , 2015, 11, 506-507.	8.0	9
121	Renal dosing of allopurinol results in suboptimal gout care. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e1-e1.	0.9	9
122	Plasma oxypurinol as a measure of adherence in clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 313-314.	0.9	9
123	Improving gout education from patients' perspectives: a focus group study of Māori and Pākehā people with gout. <i>Journal of Primary Health Care</i> , 2018, 10, 194.	0.6	9
124	How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose. <i>Arthritis Research and Therapy</i> , 2018, 20, 255.	3.5	9
125	Greenshell, � Mussels: A Review of Veterinary Trials and Future Research Directions. <i>Veterinary Sciences</i> , 2018, 5, 36.	1.7	9
126	Tapering biologic therapy for people with rheumatoid arthritis in remission: A review of patient perspectives and associated clinical evidence. <i>Musculoskeletal Care</i> , 2019, 17, 161-169.	1.4	9

#	ARTICLE	IF	CITATIONS
127	Inequities in people with gout: a focus on Māori (Indigenous People) of Aotearoa New Zealand. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110280.	2.7	9
128	Plasma interleukin-23 and circulating IL-17A+IFN γ + ex-Th17 cells predict opposing outcomes of anti-TNF therapy in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2022, 24, 57.	3.5	9
129	Frequency of CYP2C9 polymorphisms in polynesian people and potential relevance to management of gout with benzbromarone. <i>Joint Bone Spine</i> , 2014, 81, 160-163.	1.6	8
130	Rates of Joint Replacement Surgery in New Zealand, 1999â€“2015: A Comparison of Rheumatoid Arthritis and Osteoarthritis. <i>Journal of Rheumatology</i> , 2017, 44, 1823-1827.	2.0	8
131	Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays. <i>Internal Medicine Journal</i> , 2019, 49, 513-518.	0.8	8
132	Efficacy and safety of urate-lowering therapy in people with kidney impairment: a GCAN-initiated literature review. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkaa073.	0.7	8
133	Aotearoa New Zealand Māori and Pacific Population-amplified Gout Risk Variants: <i>CLNK</i> Is a Separate Risk Gene at the <i>SLC2A9</i> Locus. <i>Journal of Rheumatology</i> , 2021, 48, 1736-1744.	2.0	8
134	Assessing the Relationship Between Serum Urate and Urolithiasis Using Mendelian Randomization: An Analysis of the UK Biobank. <i>American Journal of Kidney Diseases</i> , 2021, 78, 210-218.	1.9	8
135	Reconceptualizing motivation for smoking cessation among people with rheumatoid arthritis as incentives and facilitators. <i>Musculoskeletal Care</i> , 2018, 16, 139-146.	1.4	7
136	Exploring perceptions of a rheumatoid arthritis-specific smoking cessation programme. <i>Musculoskeletal Care</i> , 2018, 16, 74-81.	1.4	7
137	ABCG2 rs2231142 (Q141K) and oxypurinol concentrations in people with gout receiving allopurinol. <i>Drug Metabolism and Pharmacokinetics</i> , 2018, 33, 241-242.	2.2	7
138	The contribution from interleukin-27 towards rheumatoid inflammation: insights from gene expression. <i>Genes and Immunity</i> , 2020, 21, 249-259.	4.1	7
139	Major unanswered questions in the clinical gout field. <i>Current Opinion in Rheumatology</i> , 2017, 29, 171-177.	4.3	6
140	Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trial. <i>Rheumatology</i> , 2018, 57, 2183-2189.	1.9	6
141	Co-expression of CD21L and IL17A defines a subset of rheumatoid synovia, characterised by large lymphoid aggregates and high inflammation. <i>PLoS ONE</i> , 2018, 13, e0202135.	2.5	6
142	No association between <i>ATP-binding cassette transporter G2</i> rs2231142 (Q141K) and urate-lowering response to febuxostat. <i>Rheumatology</i> , 2019, 58, 547-548.	1.9	6
143	Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study. <i>Internal Medicine Journal</i> , 2019, 49, 838-842.	0.8	6
144	Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response” In Search of a Minimum Effective Oxypurinol Concentration. <i>Clinical and Translational Science</i> , 2020, 13, 110-115.	3.1	6

#	ARTICLE	IF	CITATIONS
145	Trans-ancestral dissection of urate- and gout-associated major loci SLC2A9 and ABCG2 reveals primate-specific regulatory effects. <i>Journal of Human Genetics</i> , 2021, 66, 161-169.	2.3	6
146	Nortriptyline for pain in knee osteoarthritis: a double-blind randomised controlled trial in New Zealand general practice. <i>British Journal of General Practice</i> , 2021, 71, e538-e546.	1.4	6
147	Expression of the genes facilitating methotrexate action within subcutaneous rheumatoid nodules. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 943-947.	0.8	6
148	Nortriptyline in knee osteoarthritis (NortIKA Study): study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 448.	1.6	5
149	Clinical and genetic features of diuretic-associated gout: a case-control study. <i>Rheumatology</i> , 2016, 55, 1172-1176.	1.9	5
150	Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis. <i>BMJ Open</i> , 2016, 6, e012026.	1.9	5
151	Re: "Widespread prevalence of a CREBRF variant among Māori and Pacific children is associated with weight and height in early childhood". <i>International Journal of Obesity</i> , 2018, 42, 1389-1391.	3.4	5
152	Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate!. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1378-1379.	2.4	5
153	Which factors predict discordance between a patient and physician on a gout flare?. <i>Rheumatology</i> , 2021, 60, 773-779.	1.9	5
154	Variability in Urate-lowering Therapy Prescribing: A Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) Physician Survey. <i>Journal of Rheumatology</i> , 2021, 48, 152-153.	2.0	5
155	Impact of COVID-19 on health research in New Zealand: a case study of a research-intensive campus. <i>Journal of the Royal Society of New Zealand</i> , 2021, 51, S75-S85.	1.9	5
156	Elevated Urate Levels Do Not Alter Bone Turnover Markers: Randomized Controlled Trial of Inosine Supplementation in Postmenopausal Women. <i>Arthritis and Rheumatology</i> , 2021, 73, 1758-1764.	5.6	5
157	Simplification of a pharmacokinetic model for red blood cell methotrexate disposition. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1509-1516.	1.9	4
158	Lack of Evidence that Soluble Urate Directly Influences Bone Remodelling: A Laboratory and Clinical Study. <i>Calcified Tissue International</i> , 2018, 102, 73-84.	3.1	4
159	A Pilot Randomized Controlled Double-Blind Trial of High- Versus Low-Dose Weekly Folic Acid in People With Rheumatoid Arthritis Receiving Methotrexate. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 284-287.	0.9	4
160	What is remission in gout and how should we measure it?. <i>Rheumatology</i> , 2021, 60, 1007-1009.	1.9	4
161	Association of Crohn's disease-related chromosome 1q32 with ankylosing spondylitis is independent of bowel symptoms and faecal calprotectin. <i>PeerJ</i> , 2018, 6, e5088.	2.0	4
162	Effect of omega-three supplementation on serum urate and gout flares in people with gout; a pilot randomized trial. <i>BMC Rheumatology</i> , 2022, 6, .	1.6	4

#	ARTICLE	IF	CITATIONS
163	The Christchurch earthquakeâ€”providing a rheumatology service during a natural disaster. <i>Clinical Rheumatology</i> , 2012, 31, 723-725.	2.2	3
164	Influence of genetic variants on renal uric acid handling in response to frusemide: an acute intervention study. <i>RMD Open</i> , 2017, 3, e000424.	3.8	3
165	Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 241.	3.5	3
166	Formation of the Australian and New Zealand Vasculitis Society (ANZVASC) to improve the care of patients with vasculitis in Australia and New Zealand. <i>Internal Medicine Journal</i> , 2020, 50, 781-783.	0.8	3
167	Serum urate as a proposed surrogate outcome measure in gout trials: From the OMERACT working group. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1378-1385.	3.4	3
168	A Polynesian-specific copy number variant encompassing the MICA gene associates with gout. <i>Human Molecular Genetics</i> , 2022, 31, 3757-3768.	2.9	3
169	Pulmonary haemorrhage in a 13â€”year-old girl: An unusual presentation of systemic lupus erythematosus. <i>Journal of Paediatrics and Child Health</i> , 2008, 44, 743-745.	0.8	2
170	What Are the Preferences of Patients With Rheumatoid Arthritis for Treatment Modification? A Scoping Review. <i>Patient</i> , 2021, 14, 505-532.	2.7	2
171	Do Serum Urateâ€”associated Genetic Variants Influence Gout Risk in People Taking Diuretics? Analysis of the UK Biobank. <i>Journal of Rheumatology</i> , 2020, 47, 1704-1711.	2.0	2
172	HLA-B27 associated spondyloarthropathy, vasculitis, and amyloid enteropathy: response to infliximab. <i>Journal of Rheumatology</i> , 2005, 32, 382-5.	2.0	2
173	Rheumatoid interstitial lung disease in Canterbury New Zealand: prevalence, risk factors and long-term outcomesâ€”protocol for a population-based retrospective study. <i>BMJ Open</i> , 2022, 12, e050934.	1.9	2
174	Allopurinol Dose Reductions Based on Creatinine Alert Redesign System. <i>American Journal of Medicine</i> , 2016, 129, e95.	1.5	1
175	Fructose malabsorption in people with and without gout: A caseâ€”control study. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 257-263.	3.4	1
176	Allopurinol et fonction rÃ©nale. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2016, 83, 328-333.	0.0	0
177	Reply. <i>Arthritis and Rheumatology</i> , 2019, 71, 1967-1968.	5.6	0
178	Longitudinal development of incident gout from low-normal baseline serum urate concentrations: individual participant data analysis. <i>BMC Rheumatology</i> , 2021, 5, 33.	1.6	0
179	Is repeat serum urate testing superior to a single test to predict incident gout over time?. <i>PLoS ONE</i> , 2022, 17, e0263175.	2.5	0
180	Self-management of gout using a mobile app. <i>Lancet Rheumatology</i> , The, 2022, 4, e304-e305.	3.9	0

#	ARTICLE	IF	CITATIONS
181	Development of a radiographic scoring system for new bone formation in gout. Arthritis Research and Therapy, 2021, 23, 296.	3.5	0